Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AWK$142.08-0.67(-0.47%)American Water Contributes Expertise at California Water Association 2026 Summit American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., will join important conversations and contribute...[9:03:00 AM ET]TFC$48.91+0.47(+0.97%)Truist names Alex Bartlett regional president for Greater Washington and Maryland Truist Financial Corporation (NYSE: TFC) today announced Alex Bartlett has been named regional president for Greater Washington and Maryland. A...[9:03:00 AM ET]MKTW$19.58+0.75(+3.98%)MarketWise, Inc. Declares Quarterly Dividend on Class A Common Stock of $0.45 Per Share[9:00:14 AM ET]UFPI$80.93-0.30(-0.37%)UFP Packaging Expands Gulf Coast Pallet Network with Acquisition of Apache Products UFP Packaging, a division of UFP Industries (Nasdaq: UFPI), announced this week the acquisition of Apache Products, Inc., a pallet producer based in...[9:00:00 AM ET]THFF$77.70+1.24(+1.62%)First Financial Corporation Reports Third Quarter Results[9:00:00 AM ET]FTNT$181.84-1.49(-0.81%)Fortinet Expands Unified SASE to Simplify Microbranch Security[9:00:00 AM ET]VELO$6.61+0.12(+1.85%)Velo3D to Announce Third Quarter 2026 Results on November 10, 2026 Velo3D, Inc. (Nasdaq: VELO), a leading metal additive manufacturing technology company, today announced that it will release its third quarter 2026...[9:00:00 AM ET]CPB$20.53-0.10(-0.48%)Campbell's® Marks Five Years of Sides Season™ with Its Annual State of the Sides Report Campbell's officially kicked off Sides Season™ with the release of its 2026 State of the Sides Report. Now in its fifth year, the report offers a...[9:00:00 AM ET]TENB$47.55-0.66(-1.37%)Tenable Selected by Atos to Power Continuous Threat Exposure Management Program[9:00:00 AM ET]PLUR$1.23+0.11(+9.82%)Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments[9:00:00 AM ET]ATYR$0.12-0.03(-21.71%)aTyr Pharma Announces One-for-40 Reverse Stock Split[9:00:00 AM ET]KD$14.70+0.02(+0.14%)Kyndryl Opens New Cyber Defense Operations Center in Paris Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today unveiled a new Cyber Defense Operations Center in...[9:00:00 AM ET]DVN$51.27-0.37(-0.72%)NEQ Operating Strengthens Leadership Team to Support Next Phase of Growth[9:00:00 AM ET]

TRVI · NASDAQ

Trevi Therapeutics, Inc.

$12.50 -0.01 (-0.04%)

Company overview

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.8B
Employees
31
Headquarters
New Haven, CT
Website
trevitherapeutics.com
CEO
Jennifer L. Good
Listed
May 7, 2019
P/E
-38.80
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$34,000
Operating income
-$52.8M
EBITDA
-$47.3M
Net income
-$45.6M
EPS
-$0.32
Total assets
$180M
Total debt
$682,000
Earnings yield
-2.58%

Price chart

11.3613.6615.9618.2620.56
TRVI 1D NASDAQ O12.68H12.73L12.35C12.51-0.10 (-0.83%)Vol215.77K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
TRVITrevi Therapeutics, Inc. Press release Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference GlobeNewswire
TRVITrevi Therapeutics, Inc. Press release Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting GlobeNewswire
TRVITrevi Therapeutics, Inc. Stock news Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
TRVITrevi Therapeutics, Inc. Press release Trevi Therapeutics to Participate in Upcoming September Conferences GlobeNewswire
TRVITrevi Therapeutics, Inc. Press release Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 GlobeNewsWire
TRVITrevi Therapeutics, Inc. Stock news Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform Seeking Alpha
TRVITrevi Therapeutics, Inc. Stock news Trevi Therapeutics Q2 Earnings Call Highlights MarketBeat
TRVITrevi Therapeutics, Inc. Stock news Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript Seeking Alpha
TRVITrevi Therapeutics, Inc. Press release Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates GlobeNewsWire
TRVITrevi Therapeutics, Inc. Stock news Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. Fool - Investing News
TRVITrevi Therapeutics, Inc. Stock news Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript Seeking Alpha
TRVITrevi Therapeutics, Inc. Stock news Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 MarketBeat
TRVITrevi Therapeutics, Inc. Stock news Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript Seeking Alpha
TRVITrevi Therapeutics, Inc. Press release Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates GlobeNewsWire
TRVITrevi Therapeutics, Inc. Press release Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference GlobeNewsWire
TRVITrevi Therapeutics, Inc. Press release Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 GlobeNewsWire
TRVITrevi Therapeutics, Inc. Press release Trevi Therapeutics to Participate in Upcoming May Events GlobeNewsWire
TRVITrevi Therapeutics, Inc. Press release Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares GlobeNewsWire
TRVITrevi Therapeutics, Inc. Stock news What's Going On With Trevi Therapeutics Stock? Benzinga
TRVITrevi Therapeutics, Inc. Press release Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock GlobeNewsWire
See more
FAQ

Questions about Trevi Therapeutics, Inc.

What does Trevi Therapeutics, Inc. do?
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
What is TRVI's market cap?
Trevi Therapeutics, Inc. (TRVI) is a listed stock with a live quote. The latest market cap on this page is $1.8B.
Where is Trevi Therapeutics, Inc. headquartered?
Trevi Therapeutics, Inc. is headquartered in New Haven, CT.
How do I get TRVI news from the API?
Call GET /v1/news?tickers=TRVI. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does TRVI news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for TRVI, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the TRVI price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs